AR068020A1 - Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico - Google Patents
Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeuticoInfo
- Publication number
- AR068020A1 AR068020A1 ARP080103679A ARP080103679A AR068020A1 AR 068020 A1 AR068020 A1 AR 068020A1 AR P080103679 A ARP080103679 A AR P080103679A AR P080103679 A ARP080103679 A AR P080103679A AR 068020 A1 AR068020 A1 AR 068020A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptide
- amino acid
- group
- leucine
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title abstract 2
- 208000008443 pancreatic carcinoma Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 6
- 229940024606 amino acid Drugs 0.000 abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 3
- 229930182817 methionine Natural products 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 2
- 229960005277 gemcitabine Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 108010081641 arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Terapia combinada apropiada para el tratamiento del cáncer de páncreas, y Semejantes, y un método para potenciar el efecto terapéutico de agentes quimioterapéuticos tales como la gemcitabina. Reivindicacion 1: Un método para tratar un cáncer en un sujeto caracterizado porque comprende administrarle a dicho sujeto (i) y (ji): (i) uno o más péptidos seleccionados del grupo que consiste en (a) uno o más péptidos que tienen una secuencia de aminoácidos seleccionada del grupo que consiste en RFVPDGNRI (SEQ ID Ns 1), VYSSEEAEL (SEQ ID Ns 2), GYRIYDVVL (SEQ ID Ns 3), SYMISYAGM (SEQ ID Ns 4), KWEFPRDRL (SEQ ID Ns 5) y DFLTLEHLI (SEQ ID Ns 6), (b) el péptido de (a), donde se han sustituido, suprimido o agregado 1, 2 o varios aminoácidos, y donde dicho péptido puede inducir células T citotoxicas; (c) el péptido de (b), donde el segundo aminoácido desde el extremo N es fenilalanina, tirosina, metionina o triptofano; (d) el péptido de (b) o (c), donde el aminoácido C-terminal es fenilalanina, leucina, isoleucina, triptofano o metionina; (e) uno o más péptidos que tienen una secuencia de aminoácidos seleccionada del grupo que consiste en AMFFWLLLV (SEQ ID Ns 7), VIAMFFWLL (SEQ ID Ns 8), AVIAMFFWL (SEQ ID Ns 9), KLIEIGVQT (SEQ ID Ns 10), YMISYAGMV (SEQ ID Ns 11), IQSDVWSFGV (SEQ ID Ns 12) y VLAMFFWLL (SEQ ID Ns 13); (f) el péptido de (e), donde se han sustituido, suprimido o agregado 1, 2 o varios aminoácidos, y donde dicho péptido puede inducir células T citotoxicas; (g) el péptido de (f), donde el segundo aminoácido desde el extremo N es leucina o metionina; y (h) el péptido de (f) o (g), donde el aminoácido C-terminal es valina o leucina; (ii) uno o más agentes quimioterapéuticos seleccionados del grupo que consiste en gemcitabina, una sal aceptable para el uso farmacéutico de ésta y una prodroga de ésta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95792307P | 2007-08-24 | 2007-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068020A1 true AR068020A1 (es) | 2009-10-28 |
Family
ID=40386893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103679A AR068020A1 (es) | 2007-08-24 | 2008-08-22 | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8703713B2 (es) |
| EP (1) | EP2195003A4 (es) |
| JP (1) | JP5417667B2 (es) |
| KR (1) | KR20100047899A (es) |
| CN (1) | CN101883577A (es) |
| AR (1) | AR068020A1 (es) |
| AU (1) | AU2008292966C1 (es) |
| BR (1) | BRPI0815726A2 (es) |
| CA (1) | CA2697501A1 (es) |
| IL (1) | IL204143A (es) |
| MX (1) | MX2010002178A (es) |
| MY (1) | MY160406A (es) |
| NZ (1) | NZ583578A (es) |
| RU (1) | RU2472522C2 (es) |
| SG (1) | SG183770A1 (es) |
| TW (1) | TWI436775B (es) |
| UA (1) | UA100702C2 (es) |
| WO (1) | WO2009028150A1 (es) |
| ZA (1) | ZA201001580B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103951745A (zh) | 2002-09-12 | 2014-07-30 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| US20080034017A1 (en) * | 2006-08-04 | 2008-02-07 | Dominic Giampaolo | Links to a common item in a data structure |
| TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
| US20130149302A1 (en) * | 2010-05-28 | 2013-06-13 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for pancreatic cancer |
| DE102013214023B4 (de) * | 2013-07-17 | 2015-02-12 | Siemens Aktiengesellschaft | Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist |
| RU2670147C1 (ru) * | 2014-10-09 | 2018-10-18 | Ямагути Юниверсити | Вектор экспрессии car и car-экспрессирующие т-клетки |
| US10016480B2 (en) * | 2014-10-14 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Peptide-based methods for treating pancreatic cancer |
| WO2018212358A1 (ja) * | 2017-05-19 | 2018-11-22 | 学校法人慶應義塾 | 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物 |
| US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| CN114959031A (zh) * | 2022-05-20 | 2022-08-30 | 上海交通大学医学院附属瑞金医院 | 胰腺腺癌预后评估的标志物组合及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB213645A (en) | 1922-12-22 | 1924-03-24 | Frank Lincoln Morse | Improvements in and relating to chain and sprocket wheel gearing |
| US3265572A (en) | 1961-09-20 | 1966-08-09 | S B Penick And Company | Process for preparing tyrociding and product produced thereby |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DK0694042T3 (da) | 1993-03-25 | 2005-02-14 | Merck & Co Inc | Inhibitor af vaskulær endothelcellevækstfaktor |
| US6080728A (en) | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998031794A1 (fr) | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
| WO1999040118A1 (en) | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Antibodies against human vegf receptor kdr |
| GB9804121D0 (en) | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| EP1086705A4 (en) | 1998-05-20 | 2002-02-06 | Kyowa Hakko Kogyo Kk | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| CN103951745A (zh) * | 2002-09-12 | 2014-07-30 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| AU2005222384A1 (en) * | 2004-03-05 | 2005-09-22 | Vegenics Limited | Growth factor binding constructs materials and methods |
| CA2567836A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an egfr-inhibitor |
| SI1831237T1 (sl) | 2004-12-17 | 2009-02-28 | Lilly Co Eli | Amidno predzdravilo gemcitabina, zmesi in njihovauporaba |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| AU2008215432B2 (en) | 2007-02-16 | 2013-03-21 | Oncotherapy Science, Inc. | Vaccine therapy for choroidal neovascularization |
-
2008
- 2008-08-13 TW TW097130789A patent/TWI436775B/zh not_active IP Right Cessation
- 2008-08-19 EP EP08828542A patent/EP2195003A4/en not_active Withdrawn
- 2008-08-19 NZ NZ583578A patent/NZ583578A/en not_active IP Right Cessation
- 2008-08-19 BR BRPI0815726A patent/BRPI0815726A2/pt not_active IP Right Cessation
- 2008-08-19 US US12/674,754 patent/US8703713B2/en not_active Expired - Fee Related
- 2008-08-19 KR KR1020107005967A patent/KR20100047899A/ko not_active Ceased
- 2008-08-19 JP JP2010506728A patent/JP5417667B2/ja not_active Expired - Fee Related
- 2008-08-19 WO PCT/JP2008/002232 patent/WO2009028150A1/en not_active Ceased
- 2008-08-19 MY MYPI2010000779A patent/MY160406A/en unknown
- 2008-08-19 MX MX2010002178A patent/MX2010002178A/es active IP Right Grant
- 2008-08-19 UA UAA201002881A patent/UA100702C2/ru unknown
- 2008-08-19 CA CA2697501A patent/CA2697501A1/en not_active Abandoned
- 2008-08-19 AU AU2008292966A patent/AU2008292966C1/en not_active Ceased
- 2008-08-19 RU RU2010111139/15A patent/RU2472522C2/ru not_active IP Right Cessation
- 2008-08-19 CN CN2008801133893A patent/CN101883577A/zh active Pending
- 2008-08-19 SG SG2012063046A patent/SG183770A1/en unknown
- 2008-08-22 AR ARP080103679A patent/AR068020A1/es unknown
-
2010
- 2010-02-24 IL IL204143A patent/IL204143A/en not_active IP Right Cessation
- 2010-03-04 ZA ZA2010/01580A patent/ZA201001580B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008292966A1 (en) | 2009-03-05 |
| MX2010002178A (es) | 2010-03-18 |
| SG183770A1 (en) | 2012-09-27 |
| WO2009028150A1 (en) | 2009-03-05 |
| US8703713B2 (en) | 2014-04-22 |
| CN101883577A (zh) | 2010-11-10 |
| BRPI0815726A2 (pt) | 2016-01-05 |
| ZA201001580B (en) | 2011-02-23 |
| TWI436775B (zh) | 2014-05-11 |
| AU2008292966C1 (en) | 2013-03-14 |
| TW200914037A (en) | 2009-04-01 |
| KR20100047899A (ko) | 2010-05-10 |
| IL204143A (en) | 2013-04-30 |
| UA100702C2 (ru) | 2013-01-25 |
| NZ583578A (en) | 2012-07-27 |
| JP5417667B2 (ja) | 2014-02-19 |
| RU2010111139A (ru) | 2011-09-27 |
| US20110082088A1 (en) | 2011-04-07 |
| RU2472522C2 (ru) | 2013-01-20 |
| EP2195003A1 (en) | 2010-06-16 |
| CA2697501A1 (en) | 2009-03-05 |
| MY160406A (en) | 2017-03-15 |
| AU2008292966B2 (en) | 2012-07-19 |
| JP2010536714A (ja) | 2010-12-02 |
| EP2195003A4 (en) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| CO6190536A2 (es) | Vacunas peptidicas para canceres que expresan antigenos asociados con tumores | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
| HRP20160020T1 (hr) | Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku | |
| CL2021000549A1 (es) | Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460) | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| RU2010110564A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| JP2010536714A5 (es) | ||
| RU2013131089A (ru) | Пептиды тем8 и содержащие их вакцины | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2025121987A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 | |
| CN116710114B9 (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| BRPI1014631A2 (pt) | peptídeos e seus usos. | |
| EP4262746A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| ES2723098T3 (es) | Agonistas del péptido CRHR2 y usos de los mismos | |
| UA102274C2 (ru) | Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат | |
| US9334314B2 (en) | Peptide compounds derived from melanotransferrin and uses thereof | |
| CO6260086A2 (es) | Combinacion farmaceutica que comprende peptidos derivados de vegfr2 y gemcitabina, una sal de ella o una prodroga de ella |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |